NCT00468611View on ClinicalTrials.gov

Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

PHASE3TerminatedINTERVENTIONAL
Enrollment

510

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2009

Conditions
Multiple Sclerosis, Secondary Progressive
Interventions
DRUG

MBP8298

500mg MBP8298 IV every six months for a period of two years

Sponsors
All Listed Sponsors
lead

BioMS Technology Corp.

INDUSTRY